Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.71 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.71 |
| ▸ | POLB | P06746 | 3/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.71 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | HTT | P42858 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934096 | 0.82 | POLB (0.56) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL11821785 | 0.81 | ALDH1A1 (0.58) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL8786280 | 0.80 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL292247 | 0.79 | KMT2A (0.61) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL11820871 | 0.78 | ALDH1A1 (0.69) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL13722496 | 0.75 | MEN1 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL1818910 | 0.75 | MEN1 (0.68) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL16772670 | 0.74 | ALDH1A1 (0.49) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL9934903 | 0.74 | MAPT (0.47) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 | |
| SCHEMBL7389895 | 0.74 | PTPRG (0.51) | ALDH1A1SMN1; SMN2POLBMEN1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | claimed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | claimed |
| CN-106220618-B | Sulfur derivatives as chemokine receptor modulators | 阿勒根公司 | 2019-04-26 | — | — | CN | claimed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | claimed |
| CN-106220618-A | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | 阿勒根公司 | 2016-12-14 | — | — | CN | claimed |
| EP-3050873-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2016-08-03 | — | — | EP | claimed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | claimed |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2020-04-09 | — | — | US | disclosed |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| CN-106220618-B | Sulfur derivatives as chemokine receptor modulators | 阿勒根公司 | 2019-04-26 | — | — | CN | disclosed |
| EP-3050873-B1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN INC (US) | 2017-09-13 | — | — | EP | disclosed |
| US-9663460-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130190338-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130165460-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-8450367-B2 | Sulfur derivatives as chemokine receptor modulators | ALLERGAN, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2012082566-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | ALLERGAN, INC. (US) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157487-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-20130190338-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-20130165460-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-20130237552-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-20200109110-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-20130252984-A1 | SULFUR DERIVATIVES AS CHEMOKINE RECEPTOR MODULATORS | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-10287243-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
| US-11046644-B2 | Sulfur derivatives as chemokine receptor modulators | CX3CR1, CXCR2, CCR2 | ALDH1A1 2553/4885SMN1; SMN2 4664/4885POLB 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.